Tarlatamab Improves Overall Survival in Small Cell Lung Cancer
TARLATAMAB , a bispecific delta-like ligand 3-directed CD3 T-cell engager, received accelerated approval for the treatment of adult patients with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy in 2024. This approval was contingent upon verification of clinical benefit in a confirmatory trial .
The Randomized, open-label DeLLphi-304 trial (ClinicalTrials.gov Identifier :
NCT05740566
) evaluated the efficacy of tarlatamab in 509 adults with relapsed SCLC after platinum-based first-line chemotherapy. Study participants were randomly assigned to receive intravenous tarlatamab or STANDAR OF CARE THERAPY ( LURBINECTEDIN, TOPOTECAN, AMRUBICIN ). The primary endpoint was overall survival (OS).Interim analysis results showed tarlatamab demonstrated statistically significant and clinically meaningful improvement in OS compared with standard of care therapy . The safety profile for tarlatamab was consistent with previous data .
